Draft guidance
For NAMs, validation is the central question
Mar 1, 2026 · Added Oct 7, 2026
The development
FDA’s draft NAM guidance outlines general considerations for validation and reporting.
Our reading
Read this as a proposed framework for a defined use, not approval of an entire technology class.
The interpretation above is editorial analysis, not a claim made by the source.
US Food and Drug AdministrationDraft, nonbinding guidance, not final guidance or blanket acceptance of any particular NAM.
Read the evidence note